GameStop Corp. vs Halozyme Therapeutics Inc. Common Stock — how do they compare? GameStop Corp. trades at $26.57 (market cap $12.75B), while Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B). The key difference: GameStop Corp. and Halozyme Therapeutics Inc. Common Stock are close in size by market cap, and GameStop Corp. is more actively traded (13,026,993 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| GME | HALO | |
|---|---|---|
Market Cap | $12.75B | $12.58B |
Volume | 13,026,993 | 2,179,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $115.22 |
52-Week Low | $17.87 | $61.63 |
Typical Hold Time | 62 Days | 1 Days |
Enterprise Value | $12.03B | $14.49B |
Signals from Pluang's Aura AI — not financial advice
GME trades at $26.56, up 8.06% over 24 hours, with a bullish technical signal supported by moving averages. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, while revenue declined to $3.82 billion. Strong insider buying by CEO Ryan Cohen and directors has fueled positive sentiment, though analyst consensus remains cautious with a majority hold rating.
The outlook for GME hinges on execution of its strategic pivot to high-margin collectibles and leveraging its $4.77 billion cash position. Key risks include revenue volatility, competitive pressures, and dependence on insider confidence. Upside potential exists if earnings growth sustains, but investors face uncertainty from inconsistent profitability and high valuation multiples relative to historical performance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →